Second Sight Medical Products Inc (EYES, Financial) files its latest 10-K with SEC for the fiscal year ended on December 31, 2017. Second Sight Medical Products Inc develops, manufactures and markets implantable prosthetic devices that can restore some functional vision to patients blinded by outer retinal degenerations, such as Retinitis Pigmentosa. Second Sight Medical Products Inc has a market cap of $107.360 million; its shares were traded at around $1.89 with and P/S ratio of 17.35.
For the last quarter Second Sight Medical Products Inc reported a revenue of $3.11 million, compared with the revenue of $0.72 million during the same period a year ago. For the latest fiscal year the company reported a revenue of $7.96 million, an increase of 99.8% from last year. For the last five years Second Sight Medical Products Inc had an average revenue growth rate of 43.3% a year.
The reported loss per diluted share was 53 cents for the year, compared with the loss per share of $0.936 in the previous year. The Second Sight Medical Products Inc had an operating margin of -359.23%, compared with the operating margin of -833.38% a year before. The 10-year historical median operating margin of Second Sight Medical Products Inc is -833.38%. The profitability rank of the company is 3 (out of 10).
At the end of the fiscal year, Second Sight Medical Products Inc has the cash and cash equivalents of $7.84 million, compared with $0.54 million in the previous year. The company had no long term debt. Second Sight Medical Products Inc has a financial strength rank of 7 (out of 10).
At the current stock price of $1.89, Second Sight Medical Products Inc is traded at close to its historical median P/S valuation band of $2.09. The P/S ratio of the stock is 17.35, while the historical median P/S ratio is 19.19. The stock gained 54.03% during the past 12 months.
For the complete 20-year historical financial data of EYES, click here.
